PHU THO, VIETNAM — On June 10, 2026, Hung Vuong General Hospital, in collaboration with Mirari Import-Export Joint Stock Company (the exclusive distributor of MIRARI® in Vietnam), hosted a scientific workshop titled “Introduction and Clinical Applications of the Mirari Cold Plasma System in Medicine.”
The event drew active participation from the hospital’s Board of Directors, along with leading physicians, nurses, and medical staff from various clinical departments. The workshop served as a collaborative forum for medical professionals to update their knowledge on the latest international advancements in Cold Atmospheric Plasma (CAP) technology and evaluate its potential integration into daily clinical practice.
Over the past decade, Cold Atmospheric Plasma (CAP) has emerged as a groundbreaking innovation, garnering significant interest from the global scientific and medical communities. Peer-reviewed research indicates that cold atmospheric plasma generates a rich cocktail of reactive oxygen and nitrogen species (ROS/RNS). These active components play a vital role in:
During the workshop, delegates were introduced to the Mirari Cold Plasma System, developed by General Vibronics Inc. (Arizona, USA). Mirari is a non-invasive medical device engineered to deliver controlled cold plasma energy directly to target tissues, leveraging biological mechanisms to accelerate healing and manage pain.
A major highlight discussed during the seminar was the official recognition of cold plasma therapy by the Vietnamese Ministry of Health. Under Circular No. 23/2024/TT-BYT (effective July 1, 2026), cold plasma application for skin lesions and wound care has been formally added to the national List of Approved Medical Techniques.
This regulatory milestone provides the essential legal and professional framework for healthcare facilities to draft specialized clinical procedures, train medical staff, and roll out the therapy to patients.
Based on current scientific evidence and local clinical needs, the workshop participants highlighted several key therapeutic areas where the Mirari system shows strong clinical promise:
To standardize these applications, the delegates emphasized the importance of conducting further controlled clinical trials in Vietnam. These studies will help establish tailored protocols, confirm long-term efficacy, and expand clinical guidelines nationwide.
As one of the largest private healthcare systems in the Northern Midland and Mountainous region of Vietnam, Hung Vuong General Hospital has consistently prioritized the adoption of cutting-edge technology to enhance treatment outcomes and improve the patient experience.
The scientific workshop provided a valuable academic bridge between clinical practitioners, research institutions, and medical technology enterprises. By facilitating these multidisciplinary connections, the hospital aims to spearhead objective, high-quality clinical research to assess the efficacy of advanced systems like Mirari.
“Given our extensive work in surgery, internal medicine, rehabilitation, and advanced wound care, we recognize cold plasma as a highly promising technology for managing challenging skin lesions and chronic inflammation,” noted a hospital representative. “We will continue to review scientific data and assess feasibility for conducting clinical research projects with the Mirari system in the near future.”
This workshop reflects Hung Vuong General Hospital’s ongoing commitment to continuous professional development and medical innovation. By aligning with national directives on digital transformation and high-tech integration in healthcare, the hospital reinforces its patient-centered philosophy, delivering international-standard medical care to the residents of Phu Tho province and surrounding regions.
For more details on the event, you can access the official announcement on Hung Vuong General Hospital’s page: Hospital Event Link
This article is reviewed by the Mirari Doctor Medical Team and is provided for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. The MIRARI® Cold Plasma System is FDA 510(k) cleared for specific indications. Always consult with a qualified healthcare professional regarding any medical condition.
Last medically reviewed: June 20, 2026
